Bevan Nick, Corbidge Tim, Estape David, Hovmand Lyster Lars, Magnus Jorgen
Alexion Pharma International Operations UC, Blanchardstown, Dublin, Ireland.
BioPhorum, London, UK.
PDA J Pharm Sci Technol. 2021 Jul-Aug;75(4):374-390. doi: 10.5731/pdajpst.2019.010660. Epub 2020 Dec 21.
This article details a risk-based methodology designed to assign environmental classifications to the different operations in biopharmaceutical facilities manufacturing non-sterile (low bioburden) drug substance. Generally, environmental conditions for active pharmaceutical ingredient manufacture are established based on previous experiences or expectations or on extrapolated interpretations of current good manufacturing practices guidelines. Improvements in equipment design and operation, especially the use of closed systems, allow certain process steps to take place in controlled environment areas rather than in classified clean rooms. However, the design of facilities has not developed to reflect these technological advancements. The result is that facility designs are more complex with multiple environmental classifications, resulting in far higher capital and operational costs than necessary given the current technology and understanding. The authors propose a formal risk assessment-based methodology that is applicable in the early design phase of new facilities and facilitates the fast selection of the environmental conditions required for the different process steps. The risk assessment describes the risk to product quality or patient safety from environmental contamination, and this is expressed in terms of impact, probability, and detectability. The assessment considers growth potential in terms of time, nutrients, and temperature; bioburden limit; level of closure of the system; and the ability of the process to detect contamination to assign an environmental classification. Because closure is a key factor in the methodology, the authors propose a practical definition of closed systems, building on existing International Society for Pharmaceutical Engineering guidance. A fundamental of the assessment is that closed system operations only require controlled not classified environments, and any increase in classification does nothing further to protect the product. Results of the assessment are discussed in relation to a variety of process steps in different operating scenarios, to demonstrate how the assessment is applied. The methodology strongly supports the implementation of closed systems and demonstrates the limited need for classified areas. With fewer classified rooms, companies can reduce the complexity of facility layout and save costs without compromising patient safety or product quality.
本文详细介绍了一种基于风险的方法,该方法旨在为生物制药设施中生产非无菌(低生物负荷)原料药的不同操作确定环境分类。一般来说,活性药物成分生产的环境条件是根据以往经验或预期,或基于对现行良好生产规范指南的推断性解释而确定的。设备设计和操作的改进,尤其是封闭系统的使用,使得某些工艺步骤能够在受控环境区域而非分级洁净室中进行。然而,设施设计并未与时俱进以反映这些技术进步。结果是设施设计因具有多种环境分类而更加复杂,相较于当前技术和认知水平,导致资本和运营成本远高于必要水平。作者提出了一种基于正式风险评估的方法,该方法适用于新设施的早期设计阶段,并有助于快速选择不同工艺步骤所需的环境条件。风险评估描述了环境污染对产品质量或患者安全的风险,并以影响、概率和可检测性来表示。该评估从时间、营养物质和温度方面考虑生长潜力;生物负荷限度;系统的封闭程度;以及工艺检测污染的能力,以确定环境分类。由于封闭是该方法的关键因素,作者在现有制药工程国际协会指南的基础上,提出了封闭系统的实用定义。该评估的一个基本观点是,封闭系统操作仅需要受控而非分级的环境,提高环境分级对产品保护并无进一步作用。文中结合不同操作场景中的各种工艺步骤讨论了评估结果,以展示该评估方法的应用方式。该方法有力地支持了封闭系统的实施,并表明对分级区域的需求有限。通过减少分级洁净室数量,公司可以降低设施布局的复杂性并节省成本,同时不影响患者安全或产品质量。